Study Protocol: PrEP and Opioid Medications for PWID

Why It Matters

Integrating PrEP with opioid treatment could dramatically lower HIV transmission among PWID and inform national harm‑reduction strategies.

Key Takeaways

• Integrated PrEP with opioid agonist therapy
• Randomized, multi‑site trial enrolling 1,200 PWID
• Primary endpoint: HIV incidence reduction
• Secondary outcomes: adherence, overdose, quality of life
• Potential to reshape harm‑reduction policies

Pulse Analysis

HIV infection remains a leading cause of morbidity among people who inject drugs, yet uptake of pre‑exposure prophylaxis in this group has lagged behind other high‑risk populations. Barriers such as stigma, fragmented services, and competing health priorities often prevent PWID from accessing consistent PrEP. By pairing PrEP with opioid agonist therapy—already a cornerstone of harm‑reduction—researchers aim to create a single, low‑threshold entry point that addresses both viral risk and opioid dependence, potentially improving adherence and health outcomes.

The proposed protocol is a double‑blind, randomized controlled trial spanning six major U.S. cities, targeting 1,200 PWID aged 18‑55. Participants will receive either daily oral PrEP alongside buprenorphine/naloxone or standard care with opioid treatment alone. Primary outcomes focus on confirmed HIV seroconversions, while secondary metrics capture medication adherence via electronic monitoring, incidence of non‑fatal overdoses, and self‑reported quality‑of‑life scores. Embedded qualitative interviews will explore participant perceptions of integrated care, informing scalability and implementation pathways.

If successful, the study could provide the first robust evidence that co‑delivering PrEP and medication‑assisted treatment reduces HIV transmission more effectively than either intervention alone. Policymakers and public‑health agencies may leverage these findings to redesign funding streams, integrate services within syringe‑exchange programs, and expand insurance coverage for combined regimens. Ultimately, the trial promises to shift the paradigm of harm‑reduction from siloed interventions toward a holistic, patient‑centered model that tackles both infectious disease and substance‑use disorders simultaneously.